Roche Holding Ltd · SIX:RO
Roche — Jefferies Global Healthcare Conference London 2025
19 slides from Roche's conference presentation, Nov 18, 2025
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche Update
Roche Update Alan Hippe | CFO Roche Group Jefferies Global Healthcare Conference London 18 November 2025
Slide 4: Business update
Business update Progress on R&D excellence and portfolio Latest news flow / Outlook
Slide 5: A solid base to deliver long-lasting future growth
A solid base to deliver long-lasting future growth Emerging pipeline complemented by business development to add significant upside potential illustrative Business development ▪ BD to accelerate pipeline rejuvenation ▪ In-house pipeline with upside potential Pharma pipeline ▪ Today’s on-market Pharm
Slide 6: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio All therapeutic areas delivering strong growth; Diagnostics impacted by healthcare pricing reforms in China Diagnostics: Molecular Lab and YTD Sep 2025 sales Pathology Lab with strong growth; Core (CHFbn, YoY CER growth) Lab impacted by China healthcare +1%
Slide 7: 2025 guidance raised
2025 guidance raised LOE impact of CHF 0.8bn (CER, updated from CHF 1.0bn) expected for 2025 Group sales growth1 Mid single digit sales growth High single digit to low double digit Core EPS growth Core EPS growth1 (from high single digit growth) Dividend outlook Further increase dividend in Swiss fr
Slide 8: Business update: Progress on R&D excellence and portfolio
Business update Progress on R&D excellence and portfolio Latest Newsflow / Outlook
Slide 9: Further pipeline progression through 89bio acquisition
Further pipeline progression through 89bio acquisition* Prioritization of high-impact projects while increasing the total portfolio value Portfolio evolution (NME additions / removals) Portfolio value Average peak sales per pipeline project, CHF bn1 8 -8 +57% 81 4 -3 1 FGF21 analog -5 in MASH* 3 -4
Slide 10: 10 NMEs new to Ph III in 2025
10 NMEs new to Ph III in 2025 5 Ph III decisions taken in Q3: CT-388, CT-868, zilebesiran, cevostamab and HER2 TKI NXT007 in cevostamab in HER2 TKI in trontinemab in prasinezumab in zosurabalpin in zilebesiran in CT-388 in CT-868 in pegozafermin in hemophilia A R/R MM HER2+ BC AD PD MDR bacterial in
Slide 11: Up to 19 NMEs with launch potential by 2030
Up to 19 NMEs with launch potential by 2030 0.5-1bn peak sales 1-2bn peak sales afimkibart 2-3bn peak sales >3bn peak sales CT-388 IBD, AtD, AD, RA, MASH Obesity +/- T2D sefaxersen CT-868 IgAN T1D with BMI ≥25 zosurabalpin CT-996 Bacterial infections Obesity +/- T2D petrelintide* vamikibart Obesity
Slide 12: Roche Diagnostics: Key technologies to drive future growth
Roche Diagnostics: Key technologies to drive future growth New SBX data at ASHG, including GUINNESS WORLD RECORDSTM title for fastest DNA sequencing technique AXELIOS 1: Roche sequencing solution Accu-Chek® SmartGuide cobas® i601 Mass Spec Molecular Lab Near Patient Care Core Lab Roche sequencing so
Slide 13: Business update: Latest news flow / Outlook
Business update Progress on R&D excellence and portfolio Latest news flow / Outlook
Slide 14: Gazyva: Positive Ph III results in INS and SLE
Immunology Gazyva: Positive Ph III results in INS and SLE Ph III (REGENCY) in LN: US approval achieved on October 20th Gazyva (anti-CD20 mAb) Ph III (REGENCY) results in lupus nephritis B cell depletion vs 60 Treatment Difference 1 Rituxan4 Primary Endpoint: CRR at Week 13.4% (95% CI: 2.0 to 24.8) 7
Slide 15: Fenebrutinib: Positive Ph III for RMS and PPMS
Neurology Fenebrutinib: Positive Ph III for RMS (FENhance 2) and PPMS (FENtrepid) Once RMS study (FENhance 1) has read out, all data together to be considered for submission to regulatory authorities Ph II: ARR was low in participants receiving fenebrutinib Fenebrutinib development program DBTP (12
Slide 16: 2025: One remaining Ph III with PiaSky in aHUS
2025: One remaining Ph III with PiaSky in aHUS Compound Indication Milestone Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval / (US/EU) Lunsumio SC 3L+ FL US approval/EU filing (EU filing) Elevidys DMD EU approval Regulatory Gazyva Lupus n
Slide 17: 2026: Key newsflow outlook
2026: Key newsflow outlook* Compound Indication Milestone Lunsumio + Polivy 2L+ DLBCL US approval giredestrant + everolimus post CDKi ER+/HER2- mBC US/EU filing/ US approval Susvimo nAMD EU approval Regulatory Susvimo DME EU filing vamikibart UME US/EU filing divarasib 2L KRASG12C+ NSCLC Ph III KRAS
Slide 18: Consensus outlook 2024-29
Consensus outlook 2024-29* Growth driven by our young on-market portfolio; potential pipeline up-side Biosimilar gap (24-29) Consensus sales growth (24-29) Potential up-side 2026+ CHF Vabysmo 2.5bn Itovebi 1.1bn Ronapreve 015 bn Lucentis 0.1bn Polivy 1.0bn Assets with low to no coverage in Columvi 0
Slide 19: Doing now what patients need next
Doing now what patients need next
Roche — Jefferies Global Healthcare Conference London 2025 on 6ix